Effect of sodium valproate on somatosensory evoked potentials in juvenile myoclonic epilepsy. 2001

H Erdem, and A Yiğit, and A Culcuoğlu, and N Mutluer
Department of Neurology, Ondokuz Mayis University, Medical Faculty, Samsun, Turkey. hacererdem@superonline.com

We analysed somatosensory evoked potentials (SEPs) in the patients with juvenile myoclonic epilepsy (JME) in order to find out if sodium valproate (VPA) affects SEP latencies and amplitudes. SEPs were studied in 23 patients with JME receiving VPA monotherapy, eight patients with JME not receiving VPA, and a control group consisting of 20 healthy subjects. The N20, P24, and N34 latencies bilaterally were significantly prolonged in the JME group receiving VPA as compared with the control group. In the untreated patients the P24, and N34 latencies bilaterally and the N20-P24 interpeak latency on the right, were significantly prolonged as compared with the control group. In addition, in the patient group without treatment, the N20-P24 amplitudes bilaterally and the P24-N34 amplitudes from left sided median nerve stimulation, were greater as compared with the control group. In the SEP latencies, no significant differences were observed between the patients treated and untreated with VPA. Regarding SEP amplitudes, in the untreated group, while the N20-P24 amplitudes from right sided median nerve stimulation were significantly enhanced, all the other amplitudes also showed increase, even insignificant, as compared with the patients treated by VPA. These findings suggest that the SEPs latencies are prolonged, and the amplitudes are enhanced in JME. The changes of the SEPs latency in JME could be due to abnormal synaptic transmission and not influenced by VPA. On the other hand, the increase of the amplitude tends to be lowered by VPA.

UI MeSH Term Description Entries
D008297 Male Males
D011930 Reaction Time The time from the onset of a stimulus until a response is observed. Response Latency,Response Speed,Response Time,Latency, Response,Reaction Times,Response Latencies,Response Times,Speed, Response,Speeds, Response
D012016 Reference Values The range or frequency distribution of a measurement in a population (of organisms, organs or things) that has not been selected for the presence of disease or abnormality. Normal Range,Normal Values,Reference Ranges,Normal Ranges,Normal Value,Range, Normal,Range, Reference,Ranges, Normal,Ranges, Reference,Reference Range,Reference Value,Value, Normal,Value, Reference,Values, Normal,Values, Reference
D005073 Evoked Potentials, Somatosensory The electric response evoked in the CEREBRAL CORTEX by stimulation along AFFERENT PATHWAYS from PERIPHERAL NERVES to CEREBRUM. Somatosensory Evoked Potentials,Evoked Potential, Somatosensory,Somatosensory Evoked Potential
D005260 Female Females
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D000293 Adolescent A person 13 to 18 years of age. Adolescence,Youth,Adolescents,Adolescents, Female,Adolescents, Male,Teenagers,Teens,Adolescent, Female,Adolescent, Male,Female Adolescent,Female Adolescents,Male Adolescent,Male Adolescents,Teen,Teenager,Youths
D000328 Adult A person having attained full growth or maturity. Adults are of 19 through 44 years of age. For a person between 19 and 24 years of age, YOUNG ADULT is available. Adults
D000927 Anticonvulsants Drugs used to prevent SEIZURES or reduce their severity. Anticonvulsant,Anticonvulsant Drug,Anticonvulsive Agent,Anticonvulsive Drug,Antiepileptic,Antiepileptic Agent,Antiepileptic Agents,Antiepileptic Drug,Anticonvulsant Drugs,Anticonvulsive Agents,Anticonvulsive Drugs,Antiepileptic Drugs,Antiepileptics,Agent, Anticonvulsive,Agent, Antiepileptic,Agents, Anticonvulsive,Agents, Antiepileptic,Drug, Anticonvulsant,Drug, Anticonvulsive,Drug, Antiepileptic,Drugs, Anticonvulsant,Drugs, Anticonvulsive,Drugs, Antiepileptic
D014635 Valproic Acid A fatty acid with anticonvulsant and anti-manic properties that is used in the treatment of EPILEPSY and BIPOLAR DISORDER. The mechanisms of its therapeutic actions are not well understood. It may act by increasing GAMMA-AMINOBUTYRIC ACID levels in the brain or by altering the properties of VOLTAGE-GATED SODIUM CHANNELS. Dipropyl Acetate,Divalproex,Sodium Valproate,2-Propylpentanoic Acid,Calcium Valproate,Convulsofin,Depakene,Depakine,Depakote,Divalproex Sodium,Ergenyl,Magnesium Valproate,Propylisopropylacetic Acid,Semisodium Valproate,Valproate,Valproate Calcium,Valproate Sodium,Valproic Acid, Sodium Salt (2:1),Vupral,2 Propylpentanoic Acid

Related Publications

H Erdem, and A Yiğit, and A Culcuoğlu, and N Mutluer
January 1992, Epilepsia,
H Erdem, and A Yiğit, and A Culcuoğlu, and N Mutluer
September 2019, Somatosensory & motor research,
H Erdem, and A Yiğit, and A Culcuoğlu, and N Mutluer
April 1969, Archives of neurology,
H Erdem, and A Yiğit, and A Culcuoğlu, and N Mutluer
December 1997, Psychiatry and clinical neurosciences,
H Erdem, and A Yiğit, and A Culcuoğlu, and N Mutluer
September 1999, Epileptic disorders : international epilepsy journal with videotape,
H Erdem, and A Yiğit, and A Culcuoğlu, and N Mutluer
February 1989, Acta neurologica Scandinavica,
H Erdem, and A Yiğit, and A Culcuoğlu, and N Mutluer
March 1985, Brain : a journal of neurology,
H Erdem, and A Yiğit, and A Culcuoğlu, and N Mutluer
January 2016, Epilepsy research,
H Erdem, and A Yiğit, and A Culcuoğlu, and N Mutluer
November 1996, Revue neurologique,
H Erdem, and A Yiğit, and A Culcuoğlu, and N Mutluer
April 2002, Journal of neurology,
Copied contents to your clipboard!